NASH / Fatty Liver Targeted Stack

Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH, recently renamed metabolic dysfunction-associated steatohepatitis or MASH) are among the fastest-growing causes of liver disease globally. The FDA's 2024 approval of resmetirom is the first approved therapy for NASH, but it remains a single-mechanism option (thyroid hormone receptor-β agonism) in a multi-factorial disease. The pharmacologic landscape is otherwise underdeveloped relative to the clinical need.

This stack draws on two peptides with documented hepatic-fat reduction evidence (tirzepatide, tesamorelin) plus carnosine's anti-glycation rationale relevant to advanced glycation end product accumulation in metabolic liver disease. The framework targets the metabolic, GH/IGF-1-axis, and AGE dimensions of fatty liver in parallel — distinct from the general weight-loss framing of GLP-1 monotherapy.

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

• Does adding tesamorelin to tirzepatide produce additive hepatic-fat reduction beyond tirzepatide alone?
• How does this stack compare to and combine with FDA-approved resmetirom for NASH-with-fibrosis populations?
• What are the long-term outcomes — fibrosis progression, cirrhosis-development rates, hepatocellular carcinoma — under chronic combination use?
• Are there subpopulations (visceral-obese NAFLD, T2D-NASH, post-bariatric NAFLD) where the combination has differential value?

The NASH / Fatty Liver Targeted stack is one of the more clinically-coherent combinations on the site for a specific and increasingly-prevalent liver disease. Both peptide components have documented hepatic-fat-reduction evidence, the combination logic is mechanistically defensible, and the framing — liver as the specific target — matches the underlying biology. For users with documented NAFLD/NASH, this framework is reasonable as an adjunct to evidence-based hepatology care, dietary and alcohol intervention, and weight management. It is not a replacement for liver-disease-specific clinical management.